Dr. Marshall Posner Leads the Head and Neck Oncology Program at Mount Sinai

As the medical director, Dr. Posner will lead an interdisciplinary collaboration with surgery and continue his research on viral-driven solid tumor oncology.

New York, NY
 – July 27, 2010 /Press Release/  –– 

Marshall R. Posner, MD, has been appointed Medical Director of the Head and Neck Medical Oncology program and the Cancer Clinical Trials Office (CCTO) at The Mount Sinai Medical Center. His appointment is effective on August 16th.

"As a leader in head and neck tumors, Dr. Posner has made a lasting impact on his field and his patients," said Eric M. Genden, MD, Professor and Chair, Otolaryngology, Chief of the Division of Head and Neck Oncology, The Mount Sinai Medical Center. "Dr. Posner’s diverse expertise in both clinical research in head and neck cancer and immunology makes him a welcome addition to the internationally renowned otolaryngology program at Mount Sinai."

Dr. Posner will provide leadership and enhance interdisciplinary collaboration with surgery and other sub-specialties to advance the clinical services within Head and Neck Oncology at Mount Sinai. As the Medical Director of the Cancer Clinical Trials Office (CCTO) he will oversee operations, including regulatory and staff management and protocol review and monitoring. He will provide outpatient and inpatient clinical service, while also conducting research focusing on Human Papilloma Virus (HPV), viral driven solid tumor oncology, and other oncology related diseases. Dr. Posner will have appointments in the Departments of Cell and Gene Medicine, Medicine (Division of Hematology and Medical Oncology) and Otolaryngology.

Bringing a unique background in both head and neck cancer and research on a class of drugs called human monoclonal antibodies, Dr. Posner has conducted extensive research in both areas. He is currently the Medical Director of the Head and Neck Oncology Program at the Dana-Farber Cancer Institute (DFCI), where he has significantly expanded the disease center from seeing 1,500 patients each year to 10,000. His clinical and research staff has grown and the center has been involved in 50 study protocols since 1994.

During his tenure at DFCI, Dr. Posner has been the principal investigator or co-principal investigator on several national and international Phase II and III studies on squamous cell cancer of the head and neck. By leading the research on and introducing three-drug TPF (cisplatin, fluorouracil, and docetaxel) induction therapy to clinical practice, Dr. Posner has personally had a national impact on the management of this devastating disease. Dr. Posner’s research in head and neck cancer has been published nearly 200 times in top journals, including Journal of Clinical Oncology, Annals of Oncology, Cancer, and the New England Journal of Medicine.

With a long-standing interest in immunology and antibodies, Dr. Posner also maintains an active, NIH-funded laboratory studying human monoclonal antibodies as the Director of the Human Monoclonal Antibody Laboratory at Beth Israel Deaconess Medical Center. His lab has produced human monoclonal antibodies to several viral and bacterial infections, including HIV, having developed an HIV antibody and performed one of the first clinical trials of a human antibody in HIV. He has developed translational research programs in immunodiagnostics and immunotherapy in viral-driven head and neck cancer, which he will continue to study at Mount Sinai.

"Mount Sinai is on its way to becoming one of the nation’s leading centers for cancer care and research. I am confident the recruitment of Marshall Posner to our Head and Neck Cancer program will facilitate major discoveries toward improving the treatment for these serious forms of cancer," said Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of Mount Sinai School of Medicine and Executive Vice President for Academic Affairs at The Mount Sinai Medical Center. "Dr. Posner is a pioneer in translational research in head and neck cancer and immunology, and we look forward to having someone of his caliber lead the program."

After receiving his medical degree from Tufts University School of Medicine, Dr. Posner continued his training as a medical intern and resident at Boston City Hospital. He had several fellowships in medicine and medical oncology following his residency at several prestigious hospitals: Boston University Medical School, Harvard Medical School, Dana-Farber Cancer Institute, and Peter Bent Brigham Hospital (now Brigham & Women’s Hospital). Until joining Mount Sinai, Dr. Posner was an Associate Professor of Medicine at Harvard Medical School and an active staff member at Beth Israel Deaconess Medical Center, Dana-Farber Cancer Institute, and Brigham and Women’s Hospital. 

About The Mount Sinai Medical Center

The Mount Sinai Medical Center encompasses The Mount Sinai Hospital and Mount Sinai School of Medicine. The Mount Sinai Hospital is one of the nation’s oldest, largest and most-respected voluntary hospitals. Founded in 1852, Mount Sinai today is a 1,171-bed tertiary-care teaching facility that is internationally acclaimed for excellence in clinical care. Last year, nearly 60,000 people were treated at Mount Sinai as inpatients, and there were approximately 530,000 outpatient visits to the Medical Center.

Mount Sinai School of Medicine is internationally recognized as a leader in groundbreaking clinical and basic science research, as well as having an innovative approach to medical education. With a faculty of more than 3,400 in 38 clinical and basic science departments and centers, Mount Sinai ranks among the top 20 medical schools in receipt of National Institute of Health (NIH) grants. For more information, please visit www.mountsinai.org.